Atrium Therapeutics Inc. (RNA)
RNA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | RNA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002093101 |
| SEC industry code | Pharmaceutical Preparations |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $44.6M cash; operating cash flow -$14.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 21,571,507 (2026-11-02). | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Diego, California, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $15.3M | -$4.3M | -$25.4M | $44.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $3.0M | -$20.2M | -$3.9M | $72.3M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $19.6M | -$16.6M | -$31.1M | $267.8M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q3 2026 2025-09-30 | $12.3M | -$37K | $1.1M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2025-06-30 | $3.8M | -$12.9M | -$11.9M | $0 | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2025-03-31 | $1.6M | -$7.4M | -$11.1M | $0 | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 61 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.0% |
| 1 month | -3.1% |
| 3 months | -39.1% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -54.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| VRXA | Veraxa Biotech AG | $1.04 | -5.86% | $147.8M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier